JP2007502864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502864A5 JP2007502864A5 JP2006533279A JP2006533279A JP2007502864A5 JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5 JP 2006533279 A JP2006533279 A JP 2006533279A JP 2006533279 A JP2006533279 A JP 2006533279A JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- alkyl
- alkenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 53
- 210000000130 stem cell Anatomy 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 230000002452 interceptive effect Effects 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 210000001185 bone marrow Anatomy 0.000 claims 8
- 210000005259 peripheral blood Anatomy 0.000 claims 8
- 239000011886 peripheral blood Substances 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 210000000265 leukocyte Anatomy 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 5
- 125000005251 aryl acyl group Chemical group 0.000 claims 5
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 5
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 3
- 102000000646 Interleukin-3 Human genes 0.000 claims 3
- 108010002386 Interleukin-3 Proteins 0.000 claims 3
- 210000005003 heart tissue Anatomy 0.000 claims 3
- 229940076264 interleukin-3 Drugs 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003394 haemopoietic effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910021386 carbon form Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 150000002443 hydroxylamines Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- -1 stem cell factor Proteins 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44617003A | 2003-05-23 | 2003-05-23 | |
| US10/457,034 US7354932B2 (en) | 2001-12-21 | 2003-06-06 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| PCT/US2004/015977 WO2004106493A2 (en) | 2003-05-23 | 2004-05-21 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502864A JP2007502864A (ja) | 2007-02-15 |
| JP2007502864A5 true JP2007502864A5 (enExample) | 2007-07-19 |
Family
ID=33493026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533279A Pending JP2007502864A (ja) | 2003-05-23 | 2004-05-21 | 有効性を高めたケモカインレセプタ結合複素環化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US7354932B2 (enExample) |
| EP (1) | EP1628533A4 (enExample) |
| JP (1) | JP2007502864A (enExample) |
| CA (1) | CA2522535C (enExample) |
| WO (1) | WO2004106493A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US20220409589A1 (en) * | 2001-12-21 | 2022-12-29 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP2364982A1 (en) * | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
| WO2005090308A1 (en) * | 2004-03-15 | 2005-09-29 | Anormed, Inc. | Process for the synthesis of a cxcr4 antagonist |
| DE102004023506A1 (de) * | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate |
| EP1790639B1 (en) * | 2004-08-27 | 2014-03-26 | Ono Pharmaceutical Co., Ltd. | Spirocyclic compounds and their use as cxcr4-antagonists |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| US8008312B2 (en) | 2005-01-07 | 2011-08-30 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US20090093454A1 (en) * | 2005-03-04 | 2009-04-09 | Kristjan Gudmundsson | Chemical Compounds |
| WO2007008539A2 (en) * | 2005-07-11 | 2007-01-18 | Smithkline Beecham Corporation | Pyranopyridine compounds |
| US8168783B2 (en) * | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| WO2008029276A2 (en) | 2006-02-02 | 2008-03-13 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2007132846A1 (ja) * | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| AU2009228034A1 (en) | 2008-03-28 | 2009-10-01 | Altiris Therapeutics | Chemokine receptor modulators |
| US8916605B2 (en) | 2009-03-02 | 2014-12-23 | William G. Tucker | Compounds and methods for treating cancer and viral infections |
| BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
| WO2012107465A1 (en) * | 2011-02-09 | 2012-08-16 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP6958820B2 (ja) | 2015-12-14 | 2021-11-02 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| JP7055380B2 (ja) | 2015-12-22 | 2022-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 免疫不全疾患を処置するための方法 |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3727381A4 (en) * | 2017-12-19 | 2022-01-19 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| US11949239B2 (en) | 2018-07-05 | 2024-04-02 | Hitachi Energy Switzerland Ag | Technologies for solar power system performance model tuning |
| US10548889B1 (en) * | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US12208105B2 (en) | 2018-12-03 | 2025-01-28 | The University Of North Carolina At Chapel Hill | Methods for attenuating graft-versus-host disease and opportunistic infections |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| EP0988038B1 (en) | 1997-06-02 | 2002-08-14 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| AU8576098A (en) | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL135180A0 (en) | 1997-09-30 | 2001-05-20 | Daiichi Seiyaku Co | Sulfonyl derivatives |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| CA2368047A1 (en) | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6683192B2 (en) * | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| DE60137944D1 (de) | 2000-09-15 | 2009-04-23 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| DK1317451T3 (da) | 2000-09-15 | 2006-12-18 | Anormed Inc | Kemokinreceptorbindende heterocykliske forbindelser |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| KR100883184B1 (ko) * | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| EP2371361B1 (en) * | 2001-07-31 | 2019-08-07 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US6825351B2 (en) | 2001-09-12 | 2004-11-30 | Anormed, Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| MXPA04006136A (es) * | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| WO2005090308A1 (en) | 2004-03-15 | 2005-09-29 | Anormed, Inc. | Process for the synthesis of a cxcr4 antagonist |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
-
2003
- 2003-06-06 US US10/457,034 patent/US7354932B2/en not_active Expired - Lifetime
-
2004
- 2004-05-21 JP JP2006533279A patent/JP2007502864A/ja active Pending
- 2004-05-21 EP EP04752905A patent/EP1628533A4/en not_active Withdrawn
- 2004-05-21 CA CA2522535A patent/CA2522535C/en not_active Expired - Lifetime
- 2004-05-21 WO PCT/US2004/015977 patent/WO2004106493A2/en not_active Ceased
-
2008
- 2008-02-22 US US12/036,187 patent/US20080167341A1/en not_active Abandoned
-
2012
- 2012-01-25 US US13/358,041 patent/US8778967B2/en not_active Expired - Lifetime
-
2014
- 2014-06-12 US US14/302,828 patent/US20150038509A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,698 patent/US10322111B2/en not_active Expired - Lifetime
-
2019
- 2019-04-10 US US16/380,365 patent/US20200000774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502864A5 (enExample) | ||
| US20230233579A1 (en) | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids | |
| CA2522535A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| RU2004105961A (ru) | Способы активации клеток-предшественников/стволовых клеток | |
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP2006526646A5 (enExample) | ||
| Hesse et al. | Layered double hydroxides as efficient drug delivery system of ciprofloxacin in the middle ear: an animal study in rabbits | |
| Loftus et al. | The postinjury inflammatory state and the bone marrow response to anemia | |
| JP2009504788A (ja) | 化学療法の強化方法 | |
| Couban et al. | Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients | |
| JP2005532373A5 (enExample) | ||
| JP5457196B2 (ja) | Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ | |
| Maron-Gutierrez et al. | Insult-dependent effect of bone marrow cell therapy on inflammatory response in a murine model of extrapulmonary acute respiratory distress syndrome | |
| JPWO2013054755A1 (ja) | エリスロポエチン産生促進剤 | |
| Russo et al. | Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells | |
| TWI245643B (en) | Composition for selective cancer chemotherapy | |
| DE102008010362A1 (de) | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen | |
| PT2754441E (pt) | Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina | |
| EP4313028A1 (en) | Use of the sesquiterpene lactone tomentosin in the treatment of tumors caused by lymphoid cell lines | |
| Fowler et al. | Targeting the canonical nuclear factor-κB pathway with a high-potency IKK2 inhibitor improves outcomes in a mouse model of idiopathic pneumonia syndrome | |
| AU2019398198B2 (en) | CXCR7 inhibitors for the treatment of cancer | |
| CN113694205A (zh) | 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用 | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| JP2012528184A5 (enExample) | ||
| CN119896671B (zh) | 一种化合物组合在制备治疗乳腺癌药物中的应用 |